Loading...
Loading...
PRAX| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.3M |
| Operating Expense | 57.1M |
| Operating I/L | -56.8M |
| Other Income/Expense | 4.9M |
| Interest Income | 0.0M |
| Pretax | -51.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -51.9M |
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders. Its lead product candidates include PRAX-114, a GABAA receptor modulator for major depressive disorder, and PRAX-944, a T-type calcium channel inhibitor for essential tremor. The company is also developing PRAX-562 for pediatric epilepsy, PRAX-222 for GOF SCN2A epilepsy, and a KCNT1 program for KCNT1 GOF epilepsy. Praxis has collaboration and license agreements with various pharmaceutical companies and research institutions to develop its product pipeline.
